Biosimilar Naming Reg Could Pit FDA Against WHO
This article was originally published in PharmAsia News
Executive Summary
The US FDA has said that a suffix has to be attached to biosimilar names to ‘help us,’ underscoring fundamental differences in agencies’ philosophies for adding a four-letter code.